Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for patients with serious diseases, particularly cancer and other unmet medical needs
The company leverages its expertise in molecular biology and drug development to create targeted treatments that aim to improve patient outcomes. With a strong emphasis on research and clinical trials, Incyte strives to advance its pipeline of potential medications, which includes both its proprietary compounds and collaborations with other pharmaceutical partners. Through its commitment to scientific excellence and patient-centric approaches, Incyte aims to address significant healthcare challenges and enhance the quality of life for individuals suffering from complex conditions.
Exploring INCYTE CORP's Technical Signals and Breakout Potential: Based on good technical signals, INCYTE CORP is potentially setting up for a breakout.
Consider INCYTE CORP as a top value stock. NASDAQ:INCY shines in terms of profitability, solvency, and liquidity, all while remaining very reasonably priced.
Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2024 financial results conference call and webcast for 8:00 a.m. ET on Monday, February 10, 2025.
Incyte plans a transformational 2025 with four potential drug launches, pivotal trial readouts, and significant pipeline milestones targeting billion-dollar markets.
Incyte (Nasdaq:INCY) will provide an update on commercial growth, clinical progress and significant 2025 catalysts during a presentation today at 10:30 a.m. PT at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.
Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 9,502 shares of the Company’s common stock to 14 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of January 2, 2025, and were approved by the compensation committee of the Company’s board of directors as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Incyte (Nasdaq: INCY) announced today that it will present at the 43rd Annual J. P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 am (PST).
NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQINCY) concerning possible violations of federal securities laws.
NEW YORK, NY / ACCESSWIRE / December 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQINCY) concerning possible violations of federal securities laws.
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQINCY) concerning possible violations of federal securities laws.
Incyte (Nasdaq:INCY) today announced additional results from the pivotal Phase 3 inMIND trial evaluating treatment with tafasitamab (Monjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, in combination with lenalidomide and rituximab compared with placebo plus lenalidomide and rituximab in patients with relapsed or refractory follicular lymphoma (FL). These data are featured today in the Late-breaking Session (LBA-1) at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego.
Incyte (Nasdaq:INCY) today announced results from the Phase 3 POD1UM-304 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with platinum-based chemotherapy for the treatment of adults with previously untreated non-squamous and squamous metastatic non-small cell lung cancer (NSCLC) not harboring a driver mutation. These data were featured today in a mini oral presentation at the European Society for Medical Oncology (ESMO) Asia Congress 2024, held in Singapore and virtually.
Incyte (Nasdaq:INCY) today announced that it granted restricted stock unit awards (RSUs) representing an aggregate of 7,259 shares of the Company’s common stock to 15 new employees. The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of December 2, 2024, and were approved by the compensation committee of the Company’s board of directors as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
Incyte (Nasdaq: INCY) today announced that the Company will present new data from across its oncology portfolio at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego.
